8-K: Vistagen Therapeutics Appoints KPMG as New Independent Auditor, Replacing WithumSmith+Brown

Vistagen Therapeutics has changed its independent auditor from WithumSmith+Brown to KPMG, effective July 8, 2024, following a competitive selection process.

Summary

• Vistagen Therapeutics has appointed KPMG as its new independent registered public accounting firm, effective July 8, 2024.
• This decision follows a competitive selection process conducted by the Audit Committee of the Board of Directors.
• WithumSmith+Brown, PC was dismissed as the company's independent auditor on the same date.
• Withum's audit reports for the fiscal years ended March 31, 2023 and 2024 did not contain any adverse opinions or disclaimers, except for an explanatory paragraph in the 2023 report regarding the company's ability to continue as a going concern.
• There were no disagreements or reportable events between Vistagen and Withum during the fiscal years ended March 31, 2023 and 2024, and subsequent interim periods.
• Vistagen has confirmed that it did not consult with KPMG on any accounting or auditing matters prior to their engagement.

Sentiment

Score: 7

Explanation: The document is neutral in tone, detailing a routine change of auditors. The selection of KPMG is generally viewed positively, but the previous going concern note is a slight concern.

Positives

• The transition to a new auditor, KPMG, was a result of a competitive selection process, suggesting a thorough evaluation by the Audit Committee.
• Withum's audit reports did not contain any adverse opinions or disclaimers, indicating a clean audit history, except for the going concern note in 2023.
• There were no disagreements or reportable events between Vistagen and Withum, suggesting a smooth working relationship.

Negatives

• The change in auditors might raise questions about the reasons for the switch, although the document states it was due to a competitive selection process.
• The 2023 audit report from Withum included an explanatory paragraph regarding the company's ability to continue as a going concern, which could be a concern for investors, although this was not repeated in the 2024 report.

Risks

• The change in auditors could lead to a period of adjustment and potential increased scrutiny.
• Although the 2024 audit report did not include a going concern note, the previous year's note could still be a concern for some investors.

Future Outlook

The company will be working with KPMG for the fiscal year ending March 31, 2025.

Management Comments

• The Audit Committee conducted a competitive selection process to determine the company's independent registered public accounting firm for the fiscal year ending March 31, 2025.

Industry Context

Changes in auditors are not uncommon, but they can be significant events for publicly traded companies. The selection of a large firm like KPMG is often seen as a sign of stability and credibility.

Comparison to Industry Standards

• The selection of KPMG is consistent with industry practice for publicly traded companies, as they are one of the 'Big Four' accounting firms.
• Many companies of similar size and complexity use firms like KPMG for their auditing needs.
• The competitive selection process is also a standard practice to ensure the best fit for the company's needs.

Stakeholder Impact

• Shareholders may view the change in auditors as a positive step, given KPMG's reputation.
• The change should not have a significant impact on employees or customers.

Next Steps

• KPMG will begin its audit of Vistagen's financial statements for the fiscal year ending March 31, 2025.

Key Dates

Keywords

auditor, KPMG, WithumSmith+Brown, accounting, audit, financial statements, independent registered public accounting firm